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Peng Li1,2*, Yiren Xiao1,2, Zhixin Liu1,2* and Pentao Liu3Abstract
Laboratory mice have widely been used as tools for basic biological research and models for studying human
diseases. With the advances of genetic engineering and conditional knockout (CKO) mice, we now understand
hematopoiesis is a dynamic stepwise process starting from hematopoietic stem cells (HSCs) which are responsible
for replenishing all blood cells. Transcriptional factors play important role in hematopoiesis. In this review we
compile several studies on using genetic modified mice and humanized mice to study function of transcriptional
factors in lymphopoiesis, including T lymphocyte and Natural killer (NK) cell development. Finally, we focused on
the key transcriptional factor Bcl11b and its function in regulating T cell specification and commitment.
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Lab mice are invaluable tools in modern biomedical re-
search because of its short generation time, small size
and prolificacy in breeding. A pure genetic background
of the inbred mouse strain greatly improves the reprodu-
cibility of experiments, as individuals from the same
mouse strain are genetically identical. Currently, all the
common inbred strains in labs have been inbred for at
least 80 generations since their original isolation; thus
the genomes of all siblings of the same inbred line are
essentially identical [1]. These inbred mouse strains pro-
vide good platforms for studying the immune system
and modeling human immune disease [2-4]. In thymus,
hematopoietic cells undergo several developmental pro-
cesses to give rise to variety of T subsets which is one of
the central players in orchestrating immune responses.
Rothenberg and Taku Naito have reviewed a combin-
ation of transcription factors, including E2A, GATA3
and TCF1, which are essential to initiate T cell differenti-
ation program [5]. However the key factor of T lineage
specification and commitment in vivo is to be under-
stood. Recently, Bcl11b, a transcriptional factor, was
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reproduction in any medium, provided the orthe maintenance of T cell identity [6-8]. Deletion of
Bcl11b in T cells can cause these cells to reprogramme
into NK cells in mice [6]. Our goal here is to give an
introduction on the function of transcriptional factors,
especially Bcl11b, in T cell developmentGenetic manipulation of the mouse genome
Over-expression of targeted genes—gain-of-function
A most breakthrough advantage of using the mouse to
study the immune system and to model human disease is
the availability of a range of genetic technologies. In
1981, several groups produced transgenic mice by inject-
ing transgenic DNA into mouse pronuclei [9,10]. Import-
antly, DNA introduced into the mouse genome by this
method results in establishment of the transgene in the
germ line. This technology offers scientists the opportun-
ities to perform gain-of-function studies for specific
genes in the mouse model. Currently, DNA fragments
can be conveniently inserted into the host cell genome
by virus [11] or transposon system, such as Sleeping
Beauty [12] and PiggyBac [13,14]. Woltien K and his col-
leagues successfully reprogrammed murine and human
embryonic fibroblasts to induced pluripotent stem cell
(iPS) using doxycycline-inducible transcription factors
delivered by PB transposition [15]. However, the copy
number and the genomic position of the transgene that
integrates into the mouse genome vary in different oper-
ation. Therefore, it is difficult to control the expressionhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cept bacterial artificial chromosome transgenes [17],
transgenes usually are not large enough to contain all of
the cis-acting elements for recapitulating the endogenous
gene expression patterns [18]. In a word, loss-of-function
assays are usually recruited to study gene functions be-
sides gain-of-function assays.
Silent target genes—loss-of-function
In 1981, pluripotent mouse embryonic stem cells (ES)
were isolated from the inner cell mass of 3.5 days post-
coitum (dpc) wild type mouse embryos [19,20]. Later, it
was demonstrated that these ES cells were able to con-
tribute to the germ line in chimera mice derived from
ES cells, even after genome modification by retrovirus
[21,22]. Precise manipulation of the mouse genome was
achieved by demonstrating that homologous recombin-
ation works efficiently in mouse ES cells [23,24]. Thus a
combination of mouse ES cell manipulation and hom-
ologous recombination technologies gave birth to ‘gene
targeting’ which has revolutionized mouse genetics.
With birth of genetically engineered ‘knockout’ mice,
target mutations have been introduced to many loci to
study gene functions in the immunity. In 1990, Smithies’
and Jaenisch’s group independently generated β2-
microglobulin knockout mice in which expression of
major histocompatibility complex (MHC) class I mole-
cules was abolished. The mutant mice developed nor-
mally but had severely reduced number of CD8+
cytotoxic T lymphocytes (CTLs), indicating that MHC
class I molecules are required for the selection of MHC
class-I-restricted CD8+ T cells and for antigen recogni-
tion by these cells, but not necessary for T cell develop-
ment in general [25,26]. It is now feasible to knockout
every single gene in the mouse and observe phenotype
in this knockout mice (Figure 1) [27].
Conventionally, homologous recombination is employed
in gene targeting to insert a designed mutation into the
homologous recombination loci in mouse ES cells. These
ES cells are totipotent and when injected into mouse blas-
tocytes, these cells can differentiate into all cell types of a
chimeric mouse [28]. In addition, homologues knockout
of some important gene, such as the house keeping gene,
leads to embryonic death [29], exposing the defect of
knockout technology, as we lost the opportunist to study
function of these genes in adult mice. Conditional knock-
out mice approaches, often using the Cre-loxP site-spe-
cific recombination system, were developed to overcome
the embryonic lethality problem and to investigate gene
function temporally and spatially [30,31]. For example,
T cell development is arrested at early stages in Notch1
and Gata3 adult CKO mice, demonstrating the import-
ance of these two genes for T cell development [32].
However, either Notch1 or Gata3 deleted mice are diedduring embryonic period [33,34]. Similarly, conditional
knock out of Bcl11b in double negative (DN) 3 T lym-
phocytes induce DN3 T cell differentiate to NK cell [6],
but Bcl11b in conventional knockout mice die within
the first day after birth [35].
Humanized mice
Although the mouse is instrumental in elucidating key
processes in the immune system and revealing molecular
mechanisms of immune diseases [36,37], ethical issues
and significant species differences between mouse and
human constrain researchers to study human immune
system in vivo. Humanized mice, or mouse-human chi-
maeras, have been developed to overcome these con-
straints and are now an important research tool for the
in vivo study of human hematopoietic system. Humanized
mice are classified into two kinds: one is immune deficient
mice engrafted with hematopoietic cells or tissues, that
the other is transgenically expressing human genes. And
the latter have been previously reviewed [38]. In this re-
view, humanized mice refer to immune deficient mice that
are engrafted with hematopoietic cells or tissues. Many
important research advances have been made using huma-
nized mice as models to study human hematopoietic
system. For example, Faiyaz Notta and his colleagues
purified so far the most accurate human HSC Lin−CD34+C
D38−CD45RA−Thy1+RholoCD49f+ at single cell resolution
in immune deficient mice [39].
Several mouse strains have so far been used as recipients
of human hematopoietic cells. Scid (severe combined im-
mune deficiency) mice carry a spontaneous loss of func-
tion mutation of the Prkcdscid gene, or scid mutation
which results in severely deficient in T and B lymphocytes
and aberrant adaptive immune system [40]. Consequently,
scid mice can engraft human hematopoietic stem cells/
progenitors, mature lymphocytes and tumor cells without
rejection[41]. Though scid mice were proved to be suc-
cessful, the engraftment efficiency was usually low due to
high levels of innate immunity response in mice [42]. To
overcome this problem, Shultz LD and his colleagues [43]
generated the NOD-Scid mice (NOD/LtSzPrKdcscid/
PrKdscid) strain by introducing the scid mutation from
CB17-Scid mice into the NOD strain mice that contain
reduced NK cell activity [44]. However, NOD-Scid mice
are still not good enough in xenograft for the residual in-
nate immunity [43]. The interleukin-2 receptor γ-chain
(Il2rg) locus is an essential component of the receptor for
IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 [45]. Loss-of-
function mutation at the IL-2R γ-chain results in severe
impairments in T- and B-cell development and function,
and completely prevents NK-cell development [46]. Two
sub-strains—NOD/ShiLtSz-scid/IL2Rγnull (-NSG) and
NOD/ShiJic-scid/IL2Rγnull (NOG) which can engraft
higher human grafts were generated by introducing Il2rg-
Figure 1 General procedure for generation of a conditional knockout mouse strain by gene targeting strategies. (A) Generation of a
targeting vector containing critical exon of targeted genes (red rectangle), two loxP site (green triangle), a positive (+) selection cassette and
sequences of homology with the target locus (blue line). (B) The vector is linearized and electroporated into ES cells. (C) Correct tranformants are
selected for in the presence of a selectant (eg. G418 if a neomycin resistance cassette is present in the targeting vector). (D) Correctly targeted ES
cell clones are then identified and genetically characterized using long range PCR or Southern blot analysis. (E) The selected ES cell clones are
then microinjected into 3.5 dpc blastocysts and transplanted into the uteri of pseudopregnant females. (F) Chimeras obtained from the
microinjections are mated with wild-type mice to establish germ-line transmission of the modified allele. (G) Progeny derived from the chimeras
are characterized using long range PCR or Southern blot analysis, and a mutant mouse line that carries the desired targeted allele is established.
Li et al. Cell Regeneration 2012, 1:8 Page 3 of 13
http://www.cellregenerationjournal.com/content/1/1/8null mutations to NOD- Scid mouse independently.
[47,48]. Both NSG and NOG strains are widely used for
studying human hematopoiesis and leukemiagenesis [49].
Hematopoiesis
Hematopoiesis is the dynamic and complex develop-
mental process of the formation of new blood cells,
including red blood cells (erythrocytes), white blood
cells (leukocytes), and platelets [50]. For mammalians,
hematopoiesis can be divided into two periods, the primi-
tive hematopoiesis and definitive hematopoiesis. Primitive
hematopoiesis is referred as hematopoiesis taking place
prior to the development of the fetal liver. The termdefinitive hematopoiesis is used to describe blood forma-
tion after the formation of the fetal liver. In the mouse
embryos, primitive hematopoiesis formed at 8.0 days post-
conception (dpc 8) in the yolk sac blood islands. During
embryonic development, the location of hematopoiesis
shifts from the aorta-gonad-mesonephros (AGM) region
to the fetal liver [51]. After birth, the hematopoiesis center
migrates from the fetal liver to the bone marrow (BM),
where the special microenvironment (the endosteal niche)
supports hematopoiesis [52].
HSCs are a heterogeneous pluripotent population and
are composed of long-term HSC and short-term HSC.
Long-term HSCs are capable of self-renew for the whole
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renewal capacity for approximately 8 weeks [53]. Short-
term HSCs proliferate and differentiate to multipotent
progenitors (MPP) that give rise to common myeloid
progenitors (CMP) and common lymphoid progenitors
(CLP). CMP give rise to granulocyte macrophage pro-
genitors (GMP) and megakaryocyte erythroid progenitors
(MEPs) [54]. GMP can differentiate towards neutrophils,
monocytes, macrophages, eosinophils, basophils, and
mast cells, while MEP generate megakaryocytes and ery-
throcytes [55]. In contrast, CLP are restricted to give rise
to T cells, B cells, Natural Killer (NK) cells, and some
dendritic cells, but two studies suggest that some pro-
genitors derived from CLP retain myeloid differentiation
potentials (Figure 2) [56,57]. However, cell lineage can
be studied by over-expression or inactivation of some
key transcriptional factors in hematopoietic lineages [58].
Ectopic expression of Gata1 forced primary myeloid
progenitors differentiate to erythroid, eosinophil, and
basophil-like cell lineages, instead of macrophages and
granulocytes [59]. Similarly, expression of PU.1 and C/EBPα
in early mouse T cells endows the lymphoid T cell with
myeloid differentiation potential [56]. B and T lympho-
cytes can be reprogrammed to myeloid cells upon over
expressing PU.1, C/EBPα and/or C/EBPβ [60,61].Figure 2 Current scheme of haematopoiesis. LT-HSC, long-term
hematopoietic stem cell; MPP. Multipotent progenitor; CMP,
common myeloid progenitor; CLP, common lymphoid progenitor;
MEP, megakaryocyte erythroid progenitor; GMP, granulocyte
macrophage progenitor; NK/TP, NK/T progenitor, which have NK, T,
and myeloid cell potentials. Pro-T and Pro-B are progenitor cells that
go through several stages to eventually produce T and B cells.
Arrows indicate cell differentiation.T cell development
T cells are derived from the thymus and are important
for adaptive immune responses [62]. T cells are capable
of recognizing antigen peptides that are bound to MHC
molecules. There are two main subpopulations of T cells:
CD4+ helper T and CD8+ cytotoxic T cells. CD4+ T cells
recognize MHC II molecule complexes and secrete vari-
ous cytokines after being activated. Conversely, CD8+ T
cells recognize MHC class I molecules and exhibit cell-
killing activity after activation [63,64]. Acquired Immune
Deficiency Syndrome (AIDS) provides a vivid and tragic
illustration of the importance of T cells in immunity.
The human immunodeficiency virus (HIV), the causative
agent of AIDS, binds to the CD4 molecules which causes
depletion of CD4+ T cells in AIDS patients [65]. Without
CD4+ T cells, AIDS patients become hypersusceptible to
pathogens that normally inhabit in tissues without much
harming, and die of the opportunistic infections [66].
T cell development, which happens in the thymus,
involves progenitor homing, lineage specification and
commitment [67]. It also requires the intrathymic micro-
environment and interactions among key transcription
factors [5,68]. In adult mice, CLPs migrate from the bone
marrow to the thymus and initiate the program of T cell
development [69]. In the thymus, thymocytes are classified
into three distinct maturational—double negative (DN;
CD4-CD8-), double positive (DP; CD4+CD8+) and single-
positive (SP; CD4-CD8+ or CD4+CD8-) (Figure 3) [70].
Classically, the DN population can be further subdi-
vided into four subtypes (DN1—4) based on the level
of markers CD117 (c-Kit), CD44, and CD25 expressed
on the surface of the cell [71]. The CD117+DN1
(CD44+CD25-) subsets, also known as early T cell pre-
cursors (ETP), are thought to contain not only T
lineage potential but also B lineage and granulocyte-
monocyte potential [56,72]. Flt3/Flk2, a tyrosine kinase
receptor, endows ETP the choice to differentiate into
not only T cell, but also B cell, NK cell and macro-
phages [73]. In addition, both Gata3 (GATA-binding
protein 3) and Bcl11b are essential for ETP maintenance
and development [7,74]. Notch signaling is indispensable
for ETP [75]. Recently, T-cell factor 1 (TCF-1; also
known as transcription factor 7, T-cell specific, TCF7)
was identified as a messenger that transmit the com-
mands from Notch signal to downstream transcriptional
factor like Gata3 and Bcl11b during T cell specification
and differentiation [76].
T cell specification occurred in the course of transition
from ETP to DN2 (CD44+CD25+). During this period,
several key T cell genes, such as Bcl11b, Tcf12 (HEBAlt),
Gata3 and Notch1 are up-regulated. DN2 T cells not-
withstanding, retain the potentials to differentiate into
NK cells and myeloid cells [56,57,77]. ETPs and DN2
thymocytes initiate TCR gene rearrangements. However,
Figure 3 Stages in T cell development. Early T cell precursors (ETPs) differentiate from double negative (DN) to double positive (DP) to single
positive (SP) stages. Arrows indicate cell differentiation. Note that ETP and DN2 thymocytes contain non-T-cell options. β- and γδ- selection
occurs during the accumulation of the DN3 T cells.
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any TCRβ or TCR γδon their cell surface, which are
symbols of committed T cells. The non-T cell potentials
are lost in the DN3 (CD44-CD25+) T cell stage [73].
Some DN3 T cells successfully rearrange TCR γ- and δ-
chains instead of β-chain and differentiate into γδ-T
cells. The majority of T cells at DN3 stage commit to
the αβ-T cell lineage by further upregulating key T cell
genes and shutting down expression of genes that are
important for non-T cell lineages [78]. Co-activities of
E2A and HEB are not only crucial for TCR rearrange-
ment [79], but are also essential for T cells to regulate β
selection, positive selection and lineage-specific gene ex-
pression at the subsequent T-cell receptor checkpoint
[80]. The DN4 (CD44-CD25-) thymocytes undergo β-
selection after successful TCR βgene rearrangements
and initiate the differentiation to CD4+CD8+ double
positive (DP) cells [81].
Positive selection of the developing T-cell receptor
repertoire occurs in the thymic cortex where DP cells
(CD4+CD8+) selected via MHC class II and MHC class I
molecules will eventually become CD4+ cells and CD8+
cells, respectively [82]. During negative selection, that
strong interaction between thymocytes and antigens
would trigger Fas apoptotic signal, which in turn encour-
age apoptosis of the thymocytes [83]. After positive and
negative selections, the surviving thymocytes migrate to
the peripheral lymphoid tissues where cytokines like IL-
7 and the constant interaction between T cell and self-
peptide MHC play a critical role in T cell maintenance
[84]. Moreover, thymic epithelial-cell microenvironments
are indispensible for T cells selection and maintenance
during immune responses [85]. Some transcriptional
factors are required in T cell maturation. For example, E
protein transcription factors HEB and E2A are vital in
DP to SP transition [86]. Besides the transcriptional
factors, establishment of T cell identity is also regulated
by epigenetic modification. For instance, PU.1 and
GATA3 that are essential for T cell development arecontrolled by dynamic histone modification at promoter
region [68].
NK cell development
NK cell were first discovered by Rolf Kiessling in the
1970s, when he found a small population of large granu-
lar lymphocytes displayed cytotoxic activity against a
wide range of tumor cells in the absence of any previous
immunization with the tumors [87,88]. This population
of cells were named "natural killer" because of the initial
notion that they did not require prior activation to kill
cells. It was later shown that NK cells preferably targeted
cells that expressed low levels of MHC class I molecules,
a concept termed as "missing-self " recognition [89,90].
NK cells constitute an essential component of the innate
immune system, which, unlike the adaptive immune
system, recognizes and responds to pathogens without
requiring prior priming through clonal antigen recep-
tors. Mice with deficiencies in NK stimulatory immune-
receptors such as NKG2D and DNAM-1 are defective
in tumor surveillance in models of spontaneous malig-
nancy [91].
NK cell development occurs mainly in BM, although a
bipotent T/NK progenitor (TNKPs) containing T- and
NK-cell potentials has been identified in mouse fetal
liver and fetal thymus [92]. In BM, CLP commit to nat-
ural killer cell precursors (NKPs), which are defined as
Lin-(lineage)CD122+NK1.1-DX5- [93]. Upon CD122 ex-
pression, NKPs lose B-, T- or myeloid-cell potentials and
respond to IL-15 stimulation, which promotes NK cell
development [94]. Then, NKPs further differentiate into
immature NK cells that express NK1.1 in bone marrow
and liver [95,96]. Finally, immature NK cells differentiate
into mature NK cells and obtain NK-cell self-tolerance
by expressing inhibitory NK-cell receptors like Ly49 and
CD94-NKG2. [97]. Mature NK cells circulate in the
body as defenders to maintain homeostasis and shape
their weapons by producing Fasl, Trail, γInterferon-
IFN-γ perforin and granzymes [98]. Thymic NK cells
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conventional NK cells, the cytotoxicity in thymic NK
cells is compromised [99]. Moreover, it was reported
that NK cell progenitors (CD34+CD1a−) in human thy-
mus that eventually differentiated into functional CD56+
NK cells express bone morphogenetic protein (BMP)
receptors IA (BMPRIA), suggesting that BMP signaling
pathway was required for human thymic NK develop-
ment [100]. In addition, NKp46, a NK cell marker
encoded by Ncr1 gene, was found capable of blockading
enhanced NK cell reactivity [101]. Recent studies pro-
posed that Bcl11b was a key regulator in controlling NK
cell development as loss of Bcl11b induced T cell repro-
grammed to NK like cell [6,102].
Bcl11b
The B-cell lymphoma/leukemia 11 (Bcl11) family has
two members, Bcl11a and Bcl11b. Both of them are
Kruppel-like C2H2 type zinc finger transcription factors
[103]. Bcl11a was first discovered as a retroviral inser-
tion site (Evi9) in myeloid leukemia tumors in the BXH-
2 mouse [104]. Located at 2p16.1, Bcl11a is consists of 5
exons and encodes three different isoforms (Figure 4A).
The first three exons of Bcl11a present in all the three
isoforms. The longest isoform comprised exon 1-4,
whereas the rest two common shorter isoforms exhib-
ited alternative splicing from within exon 4 to an add-
itional exon 5. However, the exon 5 in the isoform 2 is
different from the one in the isoform 3 due to frame
shift in their exon 4.
Bcl11a is also expressed in early T cell progenitors and
is also important for T cell development. Germ-line de-
letion of Bcl11a causes neonatal lethality and an absence
of B cells at the earliest B cell development stages
[105,106]. Recipient mice of Bcl11a-deficient fetal liver
cells develop T cell leukemia [105]. Genome-wide associ-
ation studies in human have revealed association of the
Bcl11a locus with persistent fetal hemoglobin in the
adult [107,108]. Further characterization of Bcl11a mu-
tant mice also uncovers the key role of Bcl11a in the
fetal to adult expression switch of hemoglobin [109]. Be-
side of its important functions in B cell development
and the switch of hemoglobin expression, Bcl11a is
related to pancreatic beta-cell function, dysfunction of
which leads to type 2 diabetes [110]. In addition, a re-
cent study shows that Bcl11a is required in neuronal
morphogenesis and sensory wiring of the dorsal spinal
cord [111].
Bcl11b, also named Rit1 (radiation-induced tumor sup-
pressor gene 1), is the other member of the Bcl11 family
in the mouse and human genomes. Bcl11b located at
14q32.2, is consists of 4 exons and encodes 2 isoforms.
Compared to the isoform 1 of BCL11B that contains 894
amino acids, its isoform 2 lacks exon 3 and only have 823amino acids. All the 6 zinc fingers are distributed within
the exon 4. Alejandro Gutierrez and his colleagues find
that only exon 2 and 3 are responsible for encoding the
DNA binding domains [112]. some other domains within
the Bcl11b participate in protein-to-protein interactions,
including histone deacetylase (HDAC1 and HDAC2) [113],
sirtuin family protein (SIRT2) [114], metastasis-associated
proteins (MTA1 and MTA2) [115], Rb-associated protein
(RbAp46 and RbAp48) [116] and histone methyltransferase
(SUV39H1) [113] (Figure 4B).
Bcl11b was initially identified as a tumour suppressor
gene in T cells, because loss of heterogynous (LOH)
contributed to the formation of thymic lymphomas in
γ–ray irradiated mice [117,118]. In addition, BCL11B is
found to be involved in human T cell leukemia. A spe-
cific cryptic translocation, t(5;14)(q35.1;32.2), accrued in
about one fifth of T-cell adult leukemia/lymphoma (T-
ALL) patients, serves to activate expression of Hox11L2
by juxtaposition with strong T cell enhancer elements at
the 3’ of the Bcl11b locus [119,120]. Further more, a
novel chromosomal aberration, inv (14) (q11.2q32.31)
was reported in T-ALL samples. In this inversion, the 5’
part of Bcl11b, including exons 1-3, was joined to the
TRDD3 segment of the TCR δlocus. Consequently, in-
frame transcripts with truncated human BCL11B and
TCRδconstant region were highly expressed in screened
T-ALLs but not in normal T cells [121]. Interestingly,
though Bcl11b is considered as a tumour suppressor
gene, it is highly expressed in many human T cell
tumour lines and is required for their survival. Suppres-
sion of Bcl11b by RNA interference (RNAi) causes apop-
tosis of these tumour cells, possibly due to a decrease of
a cell-cycle inhibitor, p27, and an anti-apoptotic protein,
BCL-xL. This indicates involvement of the mitochon-
drial apoptotic pathway. In contrast, normal mature T
cells remained unaffected within the experimental time
period [122,123]. Therefore, Bcl11b could be an attract-
ive therapeutic RNAi target in T-cell malignancies [124].
Function of Bcl11b in early T cells
During evolution, a homolog of Bcl11b first appeared in
cartilaginous fishes. In sea lampreys, a jawless vertebrate,
expression of a Bcl11b ortholog is specifically detected
in VLRA+ cells that are similar to T lymphocytes in
vertebrates, but not in VLRB+ cells that are similar
to B lymphocytes in vertebrates [125]. In bony fish,
the Bcl11b ortholog is expressed in the thymus and
positively regulates Ccr9 expression, which encodes the
receptor for ccl25, a novel chemokine expressed in
thymic epithelium [126]. In both the mouse and human,
Bcl11b is highly expressed in T cells [35,119]. In the
hematopoietic system, Bcl11b was absent in B cells,
myeloid cells and most NK cells, but highly expressed in
T cell lineage [7]. Developmentally, its expression is
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Figure 4 Structure of human Bcl11b protein. A: The bar represents the 3 isoforms of Bcl11a. Exons 1-3 are the same in all the 3 isoforms.
Isoform 1 is the longest one containing 835 amino acids. The 4th exon contains all the 6 Zinc-fingers domains. The longest isoform comprised
exons 1-4, whereas the 2 common shorter isoforms exhibited alternative splicing from within exon 4 to an additional exon 5. B: The bar
represents the isoform 1 of Bcl11b including 4 exons and 6 Zinc-finger domains. All the 6 Zinc-finger domains are distributed within the longest
exon 4, and the exons 1–3 are in length of 214 amino acids. The 2nd and 3rd Zinc-finger domains are responsible for DNA binding. The regions
shown by lines encodes domains that bind to various Bcl11b cooperating proteins, such as HDAC1/2 (histone deacetylase), SIRT2 (sirtuin family
protein), SUV39H1 (histone methyltransferase), MTA1/2 (metastasis-associated proteins), RbAp46/48 (Rb-associated protein).
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cytes, for example, start to express Bcl11b during the
transition from ETP to DN2b stage, at a time when early
thymocytes gradually lose non-T-cell potentials, by his-
tone 3 methylation (H3) and demathylation [68], impli-
cating that Bcl11b plays an important role in this
process. Bcl11b expression is maintained at high levels
in T cells beyond DN2b stages [106]. In mice, over-
expression of Bcl11b results in the differentiation of T-
helper (Th) cells [127], whereas down-regulating or
knockout of Bcl11b induces reprogram from T cell into
NK-like cell [6]. However, function of Bcl11b in human
T cell requires further investigations.
Loss-of-function studies on Bcl11b in the mouse
demonstrated that Bcl11b is required for early T celldevelopment and the survival of T cells. Bcl11b homozy-
gous mutant knockout mice die in the first few days after
birth possibly due to neurological or other uncharacter-
ized defects [35,128,129]. Furthermore, in this Bcl11b-
deficient strain, T cell development is blocked at the
DN2-DN3 stage without obvious defects in other
hematopoietic lineages. A recent study using the same
knockout strain shows that Bcl11b-deficient thymocytes
are arrested at DN2 stage and acquires self-renewal
properties in vitro [8]. Our results, together with a study
from Rothenberg’s lab, show that Bcl11b-deficient DN1
and DN2 thymocytes stop T cell development and
acquire NK differentiation potentials in mouse thymus.
We thus named these killer cells that were repro-
grammed from T cells as induced T-to–natural killer
Figure 5 Summary of reprogram from various T cell subsets to
ITNK cells. ETP, early T cell precursors; DN, double negative; DP,
double positive; SP, single positive; ITNK, Induced T to natural killer
cells; NKP, natural killer progenitors; NK, natural killer cells. Black
arrows indicate differentiation and red arrows indicate
reprogramming.
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impaired Vβ to Dβ rearrangements and absence expres-
sion of pre-T cell receptors (pre-TCR) complex on the
cell surface [35]. In addition, thymocytes undergo pro-
found apoptosis in neonatal Bcl11b-deficient mice [35].
However, apoptosis is unlikely to be the main reason for
the failure of T cell development upon loss of Bcl11b,
because inactivation of p53 in mutant thymocytes is not
sufficient to fully restore the T cell development, even
though some immature single-positive (ISP) T cells are
indeed detected in Bcl11b-/-p53-/- embryos [130]. The
exact cause of T cell defects in Bcl11b-deficient mice thus
remained unresolved. Taken together, Bcl11b is required
for the early T cells to sustain T cell development and
suppressed non-T cell differentiation potentials.
Function of Bcl11b in mature T cells
Bcl11b plays a critical role in DP thymocytes by control-
ling positive selection of both CD4 and CD8 lineages.
Bcl11b-deficient DP thymocytes are prone to spon-
taneous apoptosis, which is possibly due to impaired
proximal TCR signaling and attenuated extracellular
signal-regulated kinase phosphorylation and calcium flux
that are required for initiation of positive selection [131].
In mice CD4+ T cells, following activation through TCR,
down-regulation of endogenous human BCL11B reduces
IL-2 expression, whereas overexpression of BCL11B aug-
ments IL-2 expression [132]. Further studies indicate
BCL11B promotes IL2 expression by binding and acti-
vating the IL2 promoter through the US1 site and by
enhancing NFKB1 (NK-kappa-B) activity [133]. For the
CD8+ T cells, Bcl11b is essential in the antigen-specific
clonal expansion and cytolytic effector function [134].
Loss of Bcl11b can also induce mature T cells, like DP
and CD8+, to differentiate into ITNK [6]. It has been
suggested that Bcl11b represses gene expression pro-
gram that are associated with mature CD4+ and CD8+
thymocytes, including Zbtb7b (Th-POK) and Runx3 that
are important for the development of mature CD4+ and
CD8+ T cells, respectively [135-137].
It is worth mention that Bcl11b haploinsufficiency is
demonstrated in thymocyte development. Compared to
wild type mice, heterozygous Bcl11b mutant mice have
fewer thymocytes. These Bcl11b+/- thymocytes are much
more prone to lymphomagenesis [138]. Moreover, in γ-
irradiated mice, Bcl11b heterozygosity promotes clonal
expansion and differentiation arrest of thymocytes [139].
Nevertheless, it was puzzling that no tumour develop-
ment has ever been reported in mice transplanted with
Bcl11b homozygous knockout progenitors from fetal live.
Reprogramming from T cells to NK-like cells
Using Bcl11b conditional knockout mice, it was demon-
strated that Bcl11b is important for both early andmature T cell development. Positively regulated by
Notch signaling, Bcl11b suppresses key NK genes ex-
pression and promotes the expression of cocktail of T
cell-associated transcription factors in T cells. Thus,
acute loss of Bcl11b makes early T cells lose their T cell
potential and differentiate to NK cells. In committed
DN3 thymocytes, Bcl11b is essential for the maintenance
of T cell identity, since every single survival Bcl11b defi-
cient DN3 T cell abandons its T cell development pro-
gram and subsequently reprograms to ITNK. Similarly,
mature T cells transdifferentiate to ITNK upon loss of
Bcl11b. In a word, Bcl11b is indispensable for T cells at
all developmental stages to sustain T cell development
and maintain T cell identity, while suppress NK cell pro-
gram (Figure 5) [6].
Bcl11b in other tissues
Besides the immune system, Bcl11b is also required in
skin, neuron and tooth development [18,129,140]. Bcl11b
is highly expressed in mouse skin during embryogenesis.
In the developing epidermis at late stage of fetal develop-
ment and in the adult skin, Bcl11b expression decreases
and becomes restricted to the proliferating cells of the
basal cell layer [17,128,129,140]. Further analysis indi-
cates that a subset of skin stem cells may express Bcl11b
[140,141]. Analysis of mice with gremline deletion of
Bcl11b shows that Bcl11b is required in skin during
development, particularly in keratinocyte proliferation
and late differentiation events [140-142]. Similarly,
BCL11B is expressed in human epidermis, and is linked
to disease progression and/or maintenance in atopic
dermatitis and allergic contact dermatitis patients [143].
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ment of corticospinal motor neurons axonal projections
to the spinal cord in vivo [128], and is also indispensable
for striatal medium spiny neurons differentiation, striatal
patch development, and the establishment of the cellular
architecture of the striatum [129]. In humans, BCL11B
expression is maintained at high levels in normal adult
striatum but significantly decreased in Huntington dis-
ease (HD) cells, because mutant Huntington striatal
neurons is sensitive to over-expression of BCL11B
[144], suggesting that sequestration and/or decreased
BCL11B expression is responsible for the deregulation
of striatal gene expression and the specificity of path-
ology that are observed in HD.
Bcl11b also participates in the regulation of epithelial
cell differentiation during tooth morphogenesis and is
highly expressed in ectodermic components of the
developing tooth. Bcl11b-deficient mice show multiple
defects at the bell stage and have abnormal incisors and
molars [142]. In addition Bcl11b plays multiple roles
in modulating cell migration, cell proliferation and
hair follicle stem cell maintenance during cutaneous
wounding [145].
Partners and downstream genes of Bcl11b
Bcl11b, also termed Ctip2 (COUP-TF interacting pro-
tein), was independently isolated for its ability to interact
with all members of the chicken ovalbumin upstream
promoter transcription factor (COUP-TF) subfamily of
orphan nuclear receptors [146]. COUP-TFs usually me-
diate transcriptional repression by recruiting nuclear re-
ceptor co-repressor (NCoR) and/or silencing mediator
for retinoid and thyroid hormone receptor (SMRT) to
the template. COUP-TF family members play important
roles in pattern formation in the developing nervous sys-
tems of xenopus and drosophila [146-148]. As a COUP-
TF-interacting protein, Bcl11b mediates transcriptional
repression when tethered to a promoter by interacting
with a DNA binding protein, such as ARP1, which is a
member of COUP-TF subfamily of orphan nuclear
receptors [146]. BCL11B also interacts with two metas-
tasis associated proteins MTA1 and MTA2 directly
[115]. In HEK293 cells, BCL11B recruits sirtuin 1
(SIRT1) that is a trichostatin-insensitive, nicotinamide-
sensitive class III histone deacetylase to the promoter re-
gion of a reporter gene template [114,149]. In addition,
BCL11B recruits histone deacetylase 1 (HDAC1) and
HDAC2 to promote local histone H3 deacetylation at
the HIV-1 promoter region [113].
To regulates cell cycle. Bcl11b cooperates with SUV39H1
and histone methylase to silence Cdkn1a (p21) [150].
Cdkn1a (p21) is a major cell cycle regulator which can re-
spond to DNA damage senescence and tumor suppression
[151]. In addition, Bcl11b can also repress another cyclin-dependent kinase inhibitor, Cdkn1c (p57KIP2) [152], which
is able to associate with and inhibit the catalytic activity of
a number of cylin-cdk complexes [153]. A recent study
proposes that the up-stream regulator of Bcl11b is TCF-1
which is activated by Notch1 signals [76].
Conclusions
The Immune system is the central defender against out-
side pathogen and neoplasm. The importance of human
immune system cannot be too much investigated. So far,
millions of patients have been saved for the newly found
drugs which are screened or designed by the mounting in-
formation about immunological response and tumourgen-
esis. However, progresses are impeded by in vivo study of
human immunology and ethic constrains. Since the gen-
ome and their the immune system between human and
mouse is similar, making mouse the most widely used
model in elucidating key processes of the immune system
and in revealing molecular mechanisms of immunological
diseases [36,37]. Based on gene manipulation and
humanize mice, the mask of many genes related to im-
mune and hematopoietic system, including Bcl11b, Gata3
and TCF1, are unveiled. So far, programs of the whole
genome knockout mice, like the Knockout Mouse Project
(KOMP) and the European Conditional Mouse Mutagen-
esis Program (EUCOMM), have generated thousands of
conventional and conditional knockout mouse strains and
are distributing them worldwide [154]. Furthermore, with
the development of zinc nuclease fingers and TALENs
technologies, it is easier to generate gene knockout and
knock-in mice. Thus, we expect, in the coming years, the
genome engineering technologies and conditional knock-
out mouse strains will be available for more labs and
researchers, so that functions of more transcription factors
will be elucidated in T cell development.
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